Managing sleep bruxism (SB) in children remains a clinical challenge due to the limited evidence-based treatment options for muscle hyperactivity in this population. This case report describes the successful use of botulinum toxin type A (BTX-A) in managing SB in an otherwise healthy eight-year-old girl. The patient received 10 units of BTX-A in each masseter muscle, administered at two points per side using anatomical landmarks and muscle palpation to guide injection. Symptom resolution was reported as early as the day after treatment, with effects lasting approximately two months and no adverse reactions observed. This is the first known report of BTX-A being used to treat bruxism in a healthy pediatric patient. The findings suggest that botulinum toxin may be a safe and effective alternative for managing muscle hyperactivity in children. Further research is needed to establish optimal dosing protocols and long-term safety.
Mallaguti et al. (Fri,) studied this question.